About ivosidenib
Isocitrate dehydrogenase-1 inhibitor
Used for
- Treats certain acute myeloid leukemia cases with an IDH1 mutation.
- Treats certain previously treated bile duct cancers with an IDH1 mutation.
Usual adult dose
Usually 500 mg by mouth once daily; treatment duration depends on cancer and response.
Common side effects
- Nausea, diarrhea, vomiting, or loss of appetite.
- Fatigue, swelling, or joint pain.
- Differentiation syndrome, which can be life-threatening.
- QT prolongation, potentially causing serious abnormal heart rhythms.
Important warnings
- Differentiation syndrome can occur and may be fatal; prompt treatment is essential.
- Can cause QT prolongation; monitoring and electrolyte checks may be needed.
- Can cause Guillain-Barré syndrome, a serious nerve disorder.
- Use only for cancers confirmed to have an IDH1 mutation.
Pregnancy
May harm an unborn baby. Pregnancy testing and effective contraception are recommended during treatment and for one month afterward.
Breastfeeding
Do not breastfeed during treatment or for one month after the last dose.
Interactions
- Strong CYP3A4 inhibitors can raise ivosidenib levels; dose adjustment may be needed.
- Strong CYP3A4 inducers can reduce levels and should generally be avoided.
- May reduce hormonal contraceptive effectiveness; use nonhormonal contraception.
- Avoid other medicines that prolong the QT interval when possible.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.